伊马替尼治疗博来霉素诱导的肺毒性：一例病例报告及循证综述
Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence-base review.
作者信息
Banakh Iouri, Lam Alice, Tiruvoipati Ravindranath, Carney Ian, Botha John
机构信息
Department of Pharmacy Frankston Hospital Peninsula Health Frankston Vic. Australia.
Department of Intensive Care Medicine Frankston Hospital Frankston Vic.3199 Australia; School of Public Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton Vic. 3800 Australia.
出版信息
Clin Case Rep. 2016 Apr 1;4(5):486-90. doi: 10.1002/ccr3.549. eCollection 2016 May.
Abstract
The evidence supporting therapy with imatinib for bleomycin-induced pneumonitis (BIP) is equivocal. Further experience is needed to establish its role in BIP management. While it may be considered in the management of BIP, it is important to be mindful of the adverse effects including thrombocytopenia and gastrointestinal bleeding.
摘要
支持伊马替尼治疗博来霉素诱导的肺炎（BIP）的证据并不明确。需要更多经验来确定其在BIP治疗中的作用。虽然在BIP治疗中可以考虑使用伊马替尼，但重要的是要注意其不良反应，包括血小板减少和胃肠道出血。
相似文献
1
Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence-base review.
Clin Case Rep. 2016 Apr 1;4(5):486-90. doi: 10.1002/ccr3.549. eCollection 2016 May.
2
Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report.
Clin Case Rep. 2018 Sep 4;6(10):2011-2014. doi: 10.1002/ccr3.1790. eCollection 2018 Oct.
3
Bleomycin-induced pneumonitis.
Chest. 2001 Aug;120(2):617-24. doi: 10.1378/chest.120.2.617.
4
Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients.
Pharmacogenet Genomics. 2005 Jun;15(6):399-405. doi: 10.1097/01213011-200506000-00005.
5
[Effect of imatinib mesylate on bleomycin-induced pulmonary fibrosis in mice].
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007 Apr;19(4):229-32.
6
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Am J Respir Crit Care Med. 2005 Jun 1;171(11):1279-85. doi: 10.1164/rccm.200404-531OC. Epub 2005 Feb 25.
7
No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis.
Respir Med Case Rep. 2014 May 2;12:47-9. doi: 10.1016/j.rmcr.2013.12.010. eCollection 2014.
8
Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib.
Exp Lung Res. 2015 May;41(4):173-88. doi: 10.3109/01902148.2014.939312. Epub 2015 Apr 6.
9
Increased pulmonary FDG uptake in bleomycin-associated pneumonitis.
Onkologie. 2007 Jun;30(6):320-3. doi: 10.1159/000101517. Epub 2007 May 29.
10
Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma.
Ann Hematol. 2011 Jan;90(1):67-72. doi: 10.1007/s00277-010-1032-z. Epub 2010 Jul 31.
引用本文的文献
1
Rituximab and Pirfenidone in the Treatment of Steroid-Refractory Bleomycin Lung Injury.
Respirol Case Rep. 2025 Jul 14;13(7):e70228. doi: 10.1002/rcr2.70228. eCollection 2025 Jul.
2
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
J Med Virol. 2023 Jan;95(1):e28157. doi: 10.1002/jmv.28157. Epub 2022 Sep 28.
3
Imatinib Treatment for Bleomycin-Induced Pulmonary Toxicity.
Turk Thorac J. 2020 Nov;21(6):457-460. doi: 10.5152/TurkThoracJ.2020.19082. Epub 2020 Nov 1.
4
Repurposing of Kinase Inhibitors for Treatment of COVID-19.
Pharm Res. 2020 Aug 10;37(9):167. doi: 10.1007/s11095-020-02851-7.
5
Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report.
Clin Case Rep. 2018 Sep 4;6(10):2011-2014. doi: 10.1002/ccr3.1790. eCollection 2018 Oct.
本文引用的文献
1
Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo.
Respir Res. 2014 Apr 24;15(1):51. doi: 10.1186/1465-9921-15-51.
2
Avoidance of intubation during acute exacerbation of chronic obstructive pulmonary disease for a lung transplant candidate using extracorporeal carbon dioxide removal with the Hemolung.
J Thorac Cardiovasc Surg. 2013 May;145(5):e43-4. doi: 10.1016/j.jtcvs.2013.01.040. Epub 2013 Mar 15.
3
A review of current and novel therapies for idiopathic pulmonary fibrosis.
J Thorac Dis. 2013 Feb;5(1):48-73. doi: 10.3978/j.issn.2072-1439.2012.12.07.
4
Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.
J Oncol Pharm Pract. 2013 Mar;19(1):3-7. doi: 10.1177/1078155212444649. Epub 2012 Apr 13.
5
Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?
J Clin Oncol. 2011 Aug 20;29(24):e691-3. doi: 10.1200/JCO.2011.35.6733. Epub 2011 Jun 27.
6
Bleomycin lung: a case report.
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.11.2008.1175. Epub 2009 Apr 14.
7
Neuromuscular blockers in early acute respiratory distress syndrome.
N Engl J Med. 2010 Sep 16;363(12):1107-16. doi: 10.1056/NEJMoa1005372.
8
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.
9
Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
Arthritis Rheum. 2008 Aug;58(8):2538-42. doi: 10.1002/art.23694.
10
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J Clin Oncol. 2007 Sep 1;25(25):3991-4008. doi: 10.1200/JCO.2007.10.9777. Epub 2007 Jun 18.
Zotero 插件